Results of a small study recently conducted at Johns Hopkins University indicate that Revlimid may boost vaccine responses in multiple myeloma patients.

Based on these results, the researchers who organized the study believe Revlimid could be used as part of a strategy to increase immune responses against both cancer and infectious diseases.

The researchers also argue that Revlimid may help reduce infections in myeloma patients being treated with the drug.  Infections are an important challenge for myeloma patients due to the immune system dysfunction that develops during the course of the disease. …